zefit-company

[zefit-company]

Zebrafish Solutions for Preclinical Drug Development | ZEFIT 

ZEFIT is a biotech company that uses zebrafish models for early-stage drug research, focusing on anticancer drug development. It uses gene editing, automation, and AI to speed up the testing process, collaborating with over 50 biotech partners and expanding its global pharmaceutical research presence. 

Advantages of Using Zebrafish in Drug Development: 

Zebrafish, with shared genes with humans, aid researchers in comprehending human body functions and disease development, facilitating the creation of personalized treatments for specific illnesses. 

Zebrafish models aid in early detection of molecular targets and pathways, making them ideal for proof-of-concept and early validation of new drug candidates. 

Zebrafish research yields promising results in early-stage studies, benefiting major pharmaceutical companies like Novartis and Pfizer, which are reducing research and development costs and supporting regulatory applications like IND submissions. 

Zebrafish research has been recognized as robust enough to support regulatory submissions, thereby validating its reliability in preclinical studies. 

Zebrafish, once used in drug research, faced challenges in accurately delivering drugs, leading to inconsistent results. However, recent advancements in drug delivery methods, such as oral dosing and intravenous injections, allow for more precise and advanced drug studies. 

Transparent embryos enable real-time, in vivo observation of biological processes, enabling real-time monitoring of drug effects on development, behavior, and organ function. 

Zebrafish enables researchers to rapidly test numerous drug compounds simultaneously, saving time and resources during the early stages of drug. 

Zebrafish are cost-effective, flexible, and easy to work with, making them ideal for university labs and large pharmaceutical companies. 

If you are looking for an anticancer drug discovery, you can find them at ZEFIT. 

Click here if you are interested in ZEFIT services. 

View more: Zebrafish Solutions for Preclinical Drug Development. 

[zefit-company]

Advanced Solutions for Predictive Preclinical Drug Development | ZEFIT 

ZEFIT is a contract research organization (CRO) specializing in early-stage drug discovery and preclinical contract research. They offer robust in vivo assay data to minimize development risks. Their zebrafish-based strategy enhances decision-making accuracy in preclinical trials, and their approach increases the likelihood of clinical trial success through better candidate screening and evaluation. 

ZEFIT model focuses on in vivo zebrafish data for effective compound selection, utilizing integrated AI and automation for faster results. It is highly relevant to human diseases, especially in brain and metabolic issues, and allows for tailored testing and partnerships that encourage collaboration. 

ZEFIT provides accurate and predictive in vivo data for early drug development, custom screening for CNS, oncology, metabolic, and toxicology studies, and generating data that aligns with IND-enabling studies and global preclinical standards. 

The ZEFIT platform aids in drug discovery within a 3-year timeline, identifying promising compounds and optimizing them for further development. It uses advanced tools like biosignal tracking and blood-brain barrier testing to understand drug function. Combining this with AI-powered safety and effectiveness analysis in live models improves the success rate of new drug candidates. 

Zebrafish embryos enable real-time observation of drug effects in the body, unlike lab-only tests. They are small, reproducible, and cost-effective for testing large compounds. Zebrafish share 82% of disease-related genes with humans, making them a strong model for predicting drug effects in humans. Early-stage embryos avoid animal testing restrictions, allowing faster and more ethical testing. 

If you are looking for a preclinical testing, services you can find them at ZEFIT. 

Click here if you are interested in ZEFIT services. 

View more: Advanced Solutions for Predictive Preclinical Drug Development. 

[zefit-company]

Zebrafish-Based CNS Disease Models for Preclinical Research | ZEFIT 

ZEFIT is a contract research organization that utilizes zebrafish-based models to advance preclinical drug discovery, reducing reliance on traditional mammalian models and accelerating drug candidate validation. ZEFIT CNS-FITTM platform uses zebrafish for advanced modelling of central nervous system model disorders, providing cost-effective, precise, and scalable data for early-stage drug discovery. The preclinical testing platform analyses locomotor activity, neural structures, and cognitive functions, generating robust behavioral and electrophysiological datasets, making it ideal for big data-driven research. 

Key Features of the Central Nervous System Disease Model: 

Cognitive & Memory Function Testing: CNS-FITTM tests learning ability, memory retention, and behavioral adaptability in zebrafish larvae and juveniles using visual stimuli and movement tracking algorithms it helps identify cognitive impairment and alter perception under different lighting conditions, potentially aiding in screening compounds for neuroprotective effects. 

Anxiety Behavior Modelling: Zebrafish larvae are effective models for neuropsychiatric disorder research due to their measurable responses to anxiety-inducing conditions. The CNS-FITTM platform tracks thigmotaxis and reactivity to external stimuli, making it suitable for studying generalized anxiety disorder, panic disorder, and drug screening. 

Convulsion Monitoring: The central nervous system model (CNS-FITTM) is a tool for real-time monitoring of brain activity and motor responses in neurological disorders like epilepsy. It uses electrobiological recordings, seizure frequency, intensity, and duration tracking and quantification of hyperactive swimming patterns and motor spasms. This method evaluates anticonvulsant efficacy, identifies neurotoxic effects, and explores seizure pathways. 

Trusted Models for Drug Discovery: CNS-FITTM is a standardized tool for modelling disease-specific phenotypes, including Alzheimer's, Parkinson's, and epilepsy. These models provide high translational value, enabling early compound screening, mechanistic studies, and lead candidate validation in a cost-effective and time-efficient manner. 

If you are looking for an anticancer drug development, you can find them at ZEFIT. 

Click here if you are interested in ZEFIT services. 

View more: Zebrafish-Based CNS Disease Models for Preclinical Research. 

[zefit-company]

Advancing CNS Drug Discovery with Smart In-Vivo Science | ZEFIT 

ZEFIT uses zebrafish as a preclinical contract research high-throughput in vivo model for early-stage drug candidates, providing safety, efficacy, and medical relevance insights. This platform accelerates the path to commercialization by providing precise, rapid, and scalable compound evaluation. ZEFIT is developing a next-generation platform for CNS drug development, bridging the gap between early discovery and preclinical development. The high-throughput in-vivo-driven system enables rapid identification and optimization of CNS-targeting compounds, compressing the development cycle to under 3 years. 

Challenges in CNS Drug Discovery: 

The development of drugs for central nervous system disorders faces challenges such as poor translation from in vitro to in vivo models, leading to unreliable outcomes in later stages. 

The optimization of blood-brain barrier (BBB) permeability has been found to be both expensive and inefficient. 

The absence of quantitative biomarkers for evaluating the activity and progression of CNS drugs is a significant issue. 

The decision-making process on candidate compounds is delayed due to insufficient in vivo data. 

ZEFIT Innovative Solutions: 

Zebrafish-based discovery is a cost-effective and scalable vertebrate model that provides real-time, whole-organism insights into the effects of CNS drugs. 

Quantitative EEG-based biomarkers are objective indicators from biosignals that help measure brain activity and how the body responds to drugs. 

In-Vivo Big Data Integration is a tool that utilizes a growing dataset of pharmacological effects to predict compound behavior early in development. 

CNS-Focused Drug Discovery Platform: 

ZEFIT modular, efficient CNS drug development platform utilizes high-throughput in vivo screening to quickly identify compounds with therapeutic potential for CNS disorders. 

The therapeutic index optimization platform optimizes dosage ranges and treatment windows by balancing safety and efficacy. 

The stability optimization platform enhances compound durability and bioavailability by assessing chemical and biological stability early. 

The BBB delivery optimization platform develops and validates drug delivery methods that improve BBB permeability, utilizing in vivo metrics and real-time data to expedite results. 

If you are looking for a pharmaceutical innovation, you can find them at ZEFIT. 

Click here if you are interested in ZEFIT services. 

View more: Advancing CNS Drug Discovery with Smart In-Vivo Science 

[zefit-company]

Anticancer Drug Development Using Zebrafish Models | ZEFIT 

ZEFIT is a leading company in anticancer drug development, using AI-driven screening technology and in-vivo data analytics to expedite early-stage drug discovery. It uses zebrafish models for high-throughput screening, identifying and refining oncology drug candidates within a year. Anticancer drug development involves discovering, testing, and refining new treatments to combat cancer. This process includes evaluating drug efficacy, ensuring safety, and advancing promising candidates through clinical trials to secure regulatory approval for patient use.  Anticancer drug development is a rapidly evolving field that offers hope for cancer patients with more effective more effective and less toxic cancer treatments. 

Steps for the Drug Discovery Process: 

The clinical data analysis involves examining and analyzing phenotypes in clinical patients, collaborating with medical professionals to evaluate clinical-stage protocols and pharmacological data. 

The pipeline starts by involves selecting optimized animal models for pharmacological testing, ensuring they closely mimic human disease conditions. 

The pipeline then proceeds to conduct includes conducting comprehensive diagnostic tests to verify disease phenotypes in selected models and evaluating disease characteristics for research reliability. 

Then it finally validates involves validating experimental models by comparing them with clinical patient data and confirming phenotype alignment to improve translational accuracy. 

The research also involves testing reference drugs on models to determine biomarker suitability and ensuring accurate representation of disease states through biomarkers. 

The biomarker verification and expansion process entails scaling up model samples for repeated testing and performing statistical validation to ensure reliability. 

If you are looking for anticancer drug development services or new biomarker construction, ZEFIT is a right place to discuss further. 

Click here if you are interested in ZEFIT Services. 

View More: Anticancer Drug Development Using Zebrafish Models 

[zefit-company]

Drug Development Pipeline for Metabolic Diseases | ZEFIT 

ZEFIT is a company that uses AI-powered in-vivo screening with zebrafish models to identify and optimize novel drug candidates for metabolic disease research, such as diabetes, obesity, and liver diseases. ZEFIT’s technology accelerates discovery, evaluates efficacy and safety, and enhances target validation and therapeutic development, paving the way for innovative treatments. ZEFIT’s metabolic disease model refines potential drugs for metabolic disorders using advanced screening technologies and optimization strategies. 

 Drug Development Pipeline for Metabolic Disease Research: 

AI-powered zebrafish in-vivo analysis is being utilized to expedite the identification of drug candidates in drug discovery. 

Based on automated lab facilities, ZEFIT allows high-throughput screening (HTS) to improve efficiency and precision in compound selection. 

The integration of Zebrafish models enables the swift and cost-effective in vivo testing of metabolic disease treatments. 

The use of big data analytics will favor the identification of potential therapeutic targets within a year. 

The company is continually enhancing and sophisticating its drug development pipelines through strategic partnerships with top pharmaceutical companies. 

ZEFIT’s service aims to streamline lead compound optimization and safety assessment, thereby advancing promising candidates to clinical trials. 

The company focuses on innovative treatments for metabolic diseases like diabetes, obesity, and liver disorders, enhancing drug efficacy and stability through AI-based modelling and automated experimental infrastructure. 

If you are looking for metabolic disease or anticancer drug discovery platforms, you can find them at ZEFIT. 

Click here if you are interested in ZEFIT Services. 

View More: Drug Development Pipeline for Metabolic Diseases 

[zefit-company]

Revolutionizing CNS Drug Discovery with Pharmaceutical Innovation | ZEFIT 

ZEFIT is a biopharmaceutical company that uses zebrafish as an in-vivo model for drug discovery. They leverage advanced diagnostic technology based on zebrafish, as well as AI and high-throughput screening in order to accelerate, AI, and high-throughput screening to accelerate preclinical drug development, optimize efficacy, and eventually improve success rates. A high-throughput drug discovery platform can accelerate the CNS drug development process, integrating in-vivo CNS disease model with AI-driven data analysis in large scale.  

This drug discovery platform optimizes drug candidates, ensuring higher accuracy in predicting efficacy and safety. The platform aims to deliver promising CNS treatments within three years, reducing development timelines and improving success rates in novel drug discovery in CNS disease. 

Efficient Drug Candidate Discovery & Optimization: 

Zebrafish is utilized as a high-throughput vertebrate model for efficient drug candidate discovery and optimization, especially in early-stage screening. 

AI-Driven CNS Biomarker Analysis: 

By implementing its patent-prove bio signal-based biomarker (EEG), ZEFIT can precisely assess the effect of promising CNS therapeutics 

Comprehensive In-Vivo Big Data Integration: 

ZEFIT’s pipeline also includes a large-scale pharmacological database (in-vivo compound testing data) to predict creating a pharmacological database to predict drug safety and therapeutic effects. 

Improves drug formulation for long-term stability and effectiveness: 

ZEFIT has an optimized platform for designing BBB drug delivery system, to ultimately achieve better bioavailability and therapeutical index in CNS drug formulation. 

High-Throughput In-Vivo Screening:  

Zebrafish models are utilized for rapid and scalable preclinical drug testing, bridging the gap between in-vitro and in-vivo research with real-time observations. 

AI-Powered BBB Permeability Optimization: 

Machine learning models are utilized to predict and improve BBB permeability, thereby reducing the time and costs associated with BBB drug delivery assessment. 

If you are looking for a drug discovery toxicology you can find them at ZEFIT. 

Click here if you are interested in ZEFIT Services. 

View More: Revolutionizing CNS Drug Discovery with Pharmaceutical Innovation 

[zefit-company]

Preclinical Research Services for Drug Discovery | ZEFIT 

ZEFIT is a company that uses zebrafish as an early in-vivo testing model to analyze and assess new compounds, providing rapid and reliable results. They offer compound testing services to research institutes and pharmaceutical companies, using AI-based lab infrastructure to optimize drug development Platform and accelerate commercialization. The company uses zebrafish for early in vivo testing, reducing reliance on traditional animal models. The rapid life cycle of zebrafish allows for high-throughput screening, accelerating research drug approval process. Zefit's platform combines biologists and AI technology specialists to to shorten drug development process from bench to preclinic. Zefit has offered drug candidate testing services to more than 65 research institutes and pharmaceutical companies, favoring their innovation. 

 Drug Development Platform: 

ZEFIT offers advanced compound testing solutions for drug development, utilizing AI-driven efficiency and precision, reducing testing time and data discrepancy. 

The experts create customized zebrafish disease models using genome editing, ensuring optimal conditions for development and maintenance in dedicated and certified facilities. 

The experimental infrastructure utilizes advanced AI technology to improve testing speed, data reliability, and precision, reducing variability and ensuring consistent results. 

Zefit’s large scale in-vivo data can provide precise predictions of drug toxicity and efficacy, aiding in the optimization of drug candidates for further development and commercialization. 

The revolutionizing drug discovery by combining advanced biotechnology with AI, resulting in faster and more effective treatments. 

If you are looking for a high-throughput drug discovery platform in vertebrates, you can find relevant information at ZEFIT. 

For more information, please visit zefit.co.kr/en. 

View More: Preclinical Research Services for Drug Discovery 

[zefit-company]

A Revolutionary In Vivo Cancer Drug Testing Platform for Early-Stage Drug Development | ZEFIT 

ZEFIT offers Onco-FIT, a preclinical testing services using zebrafish-based in vivo models for anticancer drug discovery. Zefit provides a cell-derived xenograft model, allowing real-time visualization of tumor growth and metastasis in zebrafish larvae. This allows for rapid assessment of anticancer compounds' efficacy from anticancer compounds. 

Features of Onco-FIT: 

Zebrafish embryos offer rapid drug screening, real-time visualization, and efficient metastasis evaluation through tumor inhibition and metastasis data within 5 days, facilitated by angiogenesis and tumor cell migration analysis. 

Fluorescence microscopy is used to quantify the tumor inhibition effects of drug candidates in transparent embryos, enabling the assessment of tumor proliferation and suppression. 

Zebrafish embryos enable rapid tumor cell assessment and real-time observation of cell migration patterns. 

Accelerating data acquisition from timer cell metastasis via the vascular system rapid assessment of tumor cell dissemination via the vascular system. 

High-throughput screening for drug development often uses small molecule screening for lead compound selection, supporting various solubilities and compatibilities with various vehicle systems and targeted therapies. 

Macromolecule screening involves specialized screening for various drugs, including ADC, antibodies, biologics, nanoparticles, and gene therapy vectors, allowing stable drug concentrations and IV-based administration. 

The platform offers customizable protocols based on specific drug types and research needs, becoming a suitable option. It also supports combination treatments and sequential drug testing, becoming a suitable option for preclinical trials and industrial applications. 

If you are looking for an anticancer drug discovery platform, you can find them at ZEFIT. 

Click here if you are interested in ZEFIT Services. 

View more: A Revolutionary In Vivo Cancer Drug Testing Platform for Early-Stage Drug Development 

[zefit-company]

High-Precision Central Nervous System Model for Drug Discovery | ZEFIT 

ZEFIT a biopharmaceutical company, uses innovative zebrafish models to accelerate preclinical research, focusing on neurological disorders, and delivers efficient solutions for drug screening and early-stage development. The central nervous system model is a research Platform for studying neurological disorders and drug discovery, by using zebrafish models to accurately evaluate neurological phenotypes like locomotion, neural structure, and cognitive functions. 

Key Features of the Central Nervous System Model: 

Comprehensive neurological assessments are performed to accurately and cost-effectively evaluate locomotion, neural structures, and cognitive functions. 

Zebrafish are a reliable model for neurological research due to their shared conserved CNS genes with humans. 

Transparent zebrafish embryos enable in vivo monitoring of brain activity and disease progression, providing non-invasive and real-time monitoring. 

Advanced Data Analytics are employed to generate large-scale datasets for in-depth analysis of neurological phenotypes, as well as estimation of drug responses 

By focusing on disease-specific behaviors and electrophysiological changes, targeted disease research offers crucial insights into Alzheimer’s disease (AD), Parkinson’s disease (PD), and epilepsy. 

The CNS-FITTM model provides a reliable preclinical system for evaluating potential drug compounds for CNS disorders. 

Efficient preclinical validation ensures a reliable evaluation of potential drug candidates for CNS disorders before they proceed to clinical trials. 

If you are looking for a reliable and effective central nervous system model, you can find it at ZEFIT. 

Click here if you have any questions in ZEFIT services. 

View more: High-Precision Central Nervous System Model for Drug Discovery  

[zefit-company]

Advanced Zebrafish Models for Drug Discovery | ZEFIT 

ZEFIT is a biopharmaceutical company that uses advanced zebrafish models for drug discovery and development. They use innovative diagnostic technologies and artificial intelligence to accelerate preclinical research, particularly in neurological disorders, bridging the gap between early-stage research and clinical application. Zebrafish models are being utilized in preclinical research to expedite and ensure the precise identification of potential therapeutics. 

Advantages of the zebrafish models: 

Zebrafish offer significant advantages in disease treatment strategies due to their conserved genes, which are crucial for maintaining fundamental biological functions across organisms, making them a promising model for studying human diseases and drug discovery. 

The zebrafish model enhances disease research by efficiently identifying disease targets, providing proof-of-concept data for therapeutic strategies, and overcoming research bottlenecks in drug development by studying individual and organ levels. 

Major pharmaceutical companies like Novartis and Pfizer have reported cost reductions of over 10 million annually using zebrafish data in drug research. The FDA has accepted zebrafish-based data for Investigational New Drug applications in 2019, 2020, and 2021, highlighting its growing importance in regulatory approval processes. Zebrafish offers an efficient and ethical alternative to traditional animal models. 

Zebrafish model utilization has improved owing to advancements in drug delivery methods, including oral administration and intravenous injection. These enabled more precise drug absorption and precision in preclinical studies, making it an effective model for pharmaceutical research. 

If you are looking for a zebrafish drug development, you can find them at ZEFIT. 

Click here if you have any inquires in ZEFIT services.. 

View more: Advanced Zebrafish Models for Drug Discovery   

[zefit-company]

Enhancing Drug Safety and Efficacy Through Preclinical Testing | ZEFIT 

ZEFIT is a biotech research company specializing in the development and discovery of new drugs using zebrafish models. Zefit utilizes advanced diagnostic technologies, including the Zebrafish Microinjection Automation System (Z-MAS™) and AI-driven ortholog prediction, to accelerate high-throughput preclinical drug discovery, with a focus on neurological disorders. Ultimately, Zefit’s services aim to improve efficiency, accuracy, and cost-effectiveness in drug screening and clinical trial success rate. 

Models: 

Zebrafish models are beneficial for screening therapeutic options, thanks to their highly conserved genes (80%~), which are crucial factors for successful drug development. 

Zebrafish-based research favors identification of disease core targets and provides robust proof-of-concept data for preclinical research treatment strategies. 

Zebrafish preclinical testing data has been utilised practically in drug R&D sector, drug R&D, saving global pharmaceutical companies over 10 million annually. In 2019, 2020, and 2021, FDA Investigational New Drug applications used zebrafish research data as the sole preclinical evidence, making it a viable alternative to traditional animal testing. 

Advancements in zebrafish model techniques, including oral administration and intravenous injection, enhance precision and effectiveness in drug research, solidifying its role as a crucial preclinical model. 

Service: 

The advanced neurological phenotyping and the use of the zebrafish as an ideal CNS model enable precise evaluation of neurological functions, efficient data collection, and Comprehensive research on Alzheimer’s disease (AD), Parkinson’s disease (PD), and epilepsy. Our CNS-FITTM models accurately mimics CNS disorders for compound screening and validation. 

Drug discovery: 

Zefit is a team of experts working to streamline the early development process of disease treatment by utilizing a high-throughput drug development platform. Our innovative platform allows for the acquisition of non-clinical compounds within a year, reducing substantial time and cost of therapeutic research. 

If you are looking for a biopharmaceutical services, you can find them at ZEFIT. 

Click here if you have any further questions in ZEFIT services. 

View more: Enhancing Drug Safety and Efficacy Through Preclinical Testing